[1] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology,2016, 64(1): 73-84. [2] Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up[J].Hepatology,2015, 61(5): 1547-1554. [3] Hagstrom H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD[J].J Hepatol,2017, 67(6): 1265-1273. [4] 罗海燕,李双杰,李碧香,等.瞬时弹性成像技术对儿童肝纤维化的诊断价值研究[J].临床小儿外科杂志,2020,19(6):481-485. [5] Hashemi SA, Alavian SM, Gholami-Fesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis[J].Caspian J Intern Med,2016, 7(4): 242-252. [6] Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis[J].Hepatology,2017, 66(5): 1486-1501. [7] 沈秋龙,陈亚军,彭春辉,等.肝脏硬度测量值用于预测胆道闭锁术后五年自体肝生存的研究[J].临床小儿外科杂志,2020,19(6):486-490,512. [8] Cassinotto C, Boursier J, Ledinghen VD, et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy[J].Hepatology,2016, 63(6): 1817-1827. [9] 夏清蓉,段星星,何静波.超声弹性成像在肝纤维化中的应用进展[J].临床小儿外科杂志,2016,15(3):295-298. [10] 崔海珺, 黄清华, 罗文.实时超声弹性成像技术在肝纤维化程度评估中的应用[J].深圳中西医结合杂志, 2019,29(22):65-66. [11] 裴书芳, 丛淑珍, 冯占武,等. 实时组织弹性成像诊断肝纤维化[J].中国医学影像技术, 2010, 26(5):893-895. [12] Loomba R. Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions[J].J Hepatol,2018, 68(2): 296-304. [13] Park CC, Nguyen P, Hernandez C, et al. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease[J].Gastroenterology,2017, 152(3): 598-607. [14] Karagoz E, Ozturker C, Sonmez G. Noninvasive evaluation of liver fibrosis supersonic shear imaging or acoustic radiation force impulse imaging[J].Radiology,2016,279(3):979-980. [15] Gou SL, Su LN, Zhai YN, et al. The clinical value of hepatic extracellular volume fraction using routine multiphasic contrast-enhanced liver CT for staging liver fibrosis[J].Clin Radiol,2017, 72(3): 242-246. [16] Dyvorne HA, Jajamovich GH, Bane O, et al. Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection[J].Liver Int,2016, 36(5):659-666. [17] Kleiner DE, BRUNT EM, Natta MV, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J].Hepatology,2005, 41(6): 1313-1321. [18] Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease[J].BMC Gastroenterol,2006, 6:6. [19] Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease:A critical appraisal[J].J Hepatol,2013, 58(5): 1007-1019. [20] Lai M, Afdhal NH. Liver fibrosis determination[J].Gastroenterol Clin North Am,2019, 48(2): 281-289. [21] Ting YW, Wong SW, Anuar A, et al. Metabolic syndrome is associated with advanced liver fibrosis among pediatric patients with non-alcoholic fatty liver disease[J].Front Pediatr,2019, 7:491. [22] Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease[J].Gut,2008, 57(10): 1441-1447. [23] McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease[J].Gut,2010, 59(9): 1265-1269. [24] Younossi ZM, Page S, Rafiq N, et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis[J].Obes Surg,2011, 21(4): 431-439. [25] Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease[J].J Hepatol,2014, 60(1): 167-174. [26] Ajmera V, Perito ER, Bass NM, et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease[J].Hepatology,2017, 65(1): 65-77. [27] Polyzos SA, Slavakis A, Koumerkeridis G, et al. Noninvasive liver fibrosis tests in patients with nonalcoholic fatty liver disease: an external validation cohort[J].Horm Metab Res,2019, 51(2): 134-140. [28] Suzuki A, Angulo P, Lymp J, et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease[J].Liver Int,2005, 25(4): 779-786. [29] Shimada M, Hashimoto E, Kaneda H, et al. Nonalcoholic steatohepatitis: risk factors for liver fibrosis.[J].Hepatol Res,2002, 24(4):429-438. [30] Yoneda M, Mawatari H, Fujita K, et al. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage[J].J Gastroenterol,2007, 42(5): 375-381. [31] Elizabeth MB,Christine GJ. Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging the Histological Lesions[J].Am J Gastroenterol,1999,94(9):2467-2474. [32] Bedossa P, Poitou, C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients[J].Hepatology,2012, 56(5): 1751-1759. [33] Alkhouri N, Vito DR, Alisi A, et al. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease[J].J Hepatol,2012, 57(6): 1312-1318. [34] Kleiner DE. Histopathology, grading and staging of nonalcoholic fatty liver disease[J].Minerva Gastroenterol Dietol,2018, 64(1): 28-38.
2021, Vol. 38 
